Hospitals in Morocco, Cameroon, and South Africa recently adopted its SOPHiA artificial intelligence offering, the firm's first crop of African customers.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.
The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.
The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.